Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.370.03%
QQQ
709.600.05%
BTC/USD
77953.000.8238%
DIA
530.790.03%
GLD
402.030.19%
TLT
81.95-

Galmed Pharmaceuticals Ltd

GLMDNASDAQ
Trade with Public
Trade with Public
$4.12
0.194.94%
At close: Sep 2, 5:00 PM EST
$3.89
-0.23-5.56%
After Hours: 7:37 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentCompareStock Report

Galmed Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Galmed Pharmaceuticals (GLMD).

Analyst Consensus — 1 Analysts

1Hold
# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Apr 4, 2025Maxim GroupNaz RahmanDowngradeBuy→Hold—

Analyst Ratings News

PRO
Maxim Group Downgrades Galmed Pharmaceuticals to Hold

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023

Benzinga Insights

PRO
Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

 
Benzinga Insights

PRO
Maxim Group Downgrades Galmed Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.
Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity analyst Edward Nash downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold and lowers the price target from $5 to $1.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved